Insights from the Ebola response to address HIV and tuberculosis

Lancet Infect Dis. 2016 Mar;16(3):276-8. doi: 10.1016/S1473-3099(16)00050-5.

Authors

Ishani Pathmanathan¹, Eric S Pevzner², Barbara J Marston³, Shannon L Hader², E Kainne Dokubo²

Affiliations

¹ Division of Global HIV and TB, Center for Global Health, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA. Electronic address: ydi6@cdc.gov.
² Division of Global HIV and TB, Center for Global Health, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
³ Division of Global Health Protection, Center for Global Health, US Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.

No abstract available

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

Africa, Western / epidemiology
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / therapeutic use
Antitubercular Agents / therapeutic use
Disease Outbreaks
HIV Infections / epidemiology
HIV Infections / therapy*
Health Services
Hemorrhagic Fever, Ebola / epidemiology
Hemorrhagic Fever, Ebola / therapy*
Humans
Population Surveillance
Tuberculosis / epidemiology
Tuberculosis / therapy*

Substances

Anti-HIV Agents
Antitubercular Agents

Grants and funding